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Abstract16
Background. The prevalence of reported penicillin allergy(PenA) and the impact these17
records have on health outcomes in the UK general population are unknown. Without such18
data, justifying and planning enhanced allergy services is challenging.19
20
Objectives. Determine:1) prevalence of PenA records; 2) patient characteristics21
associated with PenA records; 3) impact of PenA records on antibiotic prescribing/health22
outcomes in primary care.23
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Methods. Cross sectional/retrospective cohort studies using patient-level data from25
electronic health records. Cohort study: exact matching across confounders identified as26
affecting PenA records. Setting: English NHS general practices between 1st April 2013 and27
31st March 2014. Participants: 2.3 million adult patients. Outcome measures: prevalence of28
PenA; antibiotic prescribing, mortality, methicillin resistant Staphylococcus aureus(MRSA)29
infection/colonisation, C. difficile infection.30
31
Results. PenA prevalence: 5.9% (interquartile range,3.8-8.2%). PenA records were more32
common in older people, females, those with co-morbidity and were affected by General33
practitioner (GP) practice. Antibiotic prescribing varied significantly: penicillins were34
prescribed less frequently in those with PenA record (relative risk (RR)0.15),35
macrolides(RR4.03), tetracyclines(RR1.91) nitrofurantoin(RR1.09), trimethoprim(RR1.04),36
cephalosporins(RR2.05), quinolones(RR2.10), clindamycin(RR5.47) and total number of37
prescriptions were increased in patients with PenA record. Risk of: re-prescription of a new38
antibiotic class within 28 days(RR 1.32); MRSA infection/colonisation(RR1.90), and; death39
during the year subsequent to 1st April 2013 increased(RR1.08) in those with PenA40
records.41
42
Conclusions. PenA records are common in the general population and associated with43
increased/altered antibiotic prescribing and worse health outcomes.44
45
Clinical implications: We estimated incorrect PenA records affect 2.7 million people in46
England. Establishing true PenA status (e.g. oral challenge testing) would allow more47
people to be prescribed first-line antibiotics potentially improving health outcomes.48
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Introduction50
Many patients have a record of penicillin allergy (PenA),1,2,3,4 but, when formally tested,51
only a small proportion are found to have a true PenA.1,5,6 “False” PenA labels can arise52
for a number of reasons, including skin reactions to the penicillin that do not constitute a53
serious allergy risk, adverse effects that have been misclassified as an allergy and54
misidentification of infection symptoms. When antibiotic treatment is considered55
necessary, clinicians generally prescribe second-line antibiotic classes for these patients,756
that may not be as effective, may impact more negatively on antimicrobial resistance and57
might not be as safe. For example, increased risk of cardiovascular mortality has been58
reported following therapy with antibiotics often used as alternatives to penicillins59
clarithromycin,8 azithromycin,9,10 and levofloxacin9 and the risk of MRSA infection is60
increased following cephalosporin11,12 clindamycin13 and fluoroquinolone12 prescribing. A61
recent analysis of general practice data has found a significant increased risk of MRSA62
and Clostridioides difficile infection in patients with a PenA record, partly attributed to63
changes in antibiotic prescribing.1464
65
PenA testing is available and reliable, so many patients who are falsely labelled as66
penicillin allergic could have their status safely reversed. However, PenA testing is67
available but not commonly carried out in general practice, partly due to GP uncertainty68
about referral criteria and knowledge about the test.15 Existing hospital allergy services are69
unable to meet the current demand for allergy testing.70
71
Precise estimates of the prevalence of PenA records and their impact on the general72
population in the United Kingdom (UK) are not available. It is unclear the extent to which73
the worse patient outcomes attributed to PenA might be explained by comorbidity, age, or74
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other factors. If a record of PenA was associated with such increased risks, then75
confirmation of allergic status in advance of need for antibiotics (a “pre-emptive” strategy)76
in primary care may have important benefits for these individuals and for antibiotic77
stewardship.78
79
To support a “pre-emptive” testing strategy, we set out to: 1) determine the prevalence of80
PenA in UK general practice records; 2) establish patient characteristics associated with a81
recorded PenA and; 3) investigate the impact on antibiotic prescribing decisions and82
health outcomes.83
84
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Methods85
Ethics approval86
The study was approved by the School of Medicine Research Ethics Committee,87
University of Leeds(REF:SoMREC/13/101). The protocol/data request also approved by88
the Project Committee at ResearchOne. ResearchOne is a research database that89
consists of de-identified clinical and administrative data drawn from the electronic patient90
records of ~6 million patients on SystmOne.16 ResearchOne has received a favourable91
opinion from NHS Research Ethics Committee North East–Newcastle and North Tyneside92
1 (REF: 11/NE/0184) and an opinion from the National Information Governance Board and93
Secretary of State for Health that no recommendation of support for Section 251 approval94
is required as there is no disclosure of identifiable data (National Research Ethics Service95
Research Ethics Committee North East REC reference number 11/NE/0184).96
97
Study Design98
This study comprised three parts:99
(1) Cross-sectional study of adult patients in ResearchOne based on their electronic100
health records at 1st April 2013. Aim: to identify factors associated with the record of101
a PenA, allowing for clustering within practice.102
(2) Retrospective cohort study with patients matched by the factors identified in Part 1.103
Patients were followed for one year until 31st March 2014 to establish the104
associated impact of a PenA record on several health outcomes.105
(3) A retrospective cohort study which included only patients prescribed at least one106
antibiotic during the study year 1st April 2013 to 31st March 2014. Patient cohorts107
with and without PenA record were matched by the factors identified in Part 1.108
Setting and source data109
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Data comprised an extract from NHS general practices in England whose routine clinical110
data was included in ResearchOne at 29th June 2016. ResearchOne has been mainly111
used in quality improvement research and to develop a frailty index.17 Patient records112
included historical contributions from 400 general practices. The one-year study period113
began 1st April 2013. Matched case control studies used a subset of the extract.114
115
Participants116
All adults (18-100 years old) with records on ResearchOne at the date of extraction.117
Eligible patients included those that had died since 1st April 2013. Patients over 100 years118
of age were excluded to reduce the risk of inadvertent identification.119
120
Variables121
Variables included: PenA records and antibiotic prescriptions from the following classes:122
penicillins, cephalosporins, clindamycin, macrolides, tetracyclines, nitrofurantoin,123
trimethoprim, quinolones, carbapenems and aztreonam; date of prescription and all124
prescriptions of drugs within the period 1st April 2013 to 31st March 2014. Additional125
variables included: age, gender, date of death, index of multiple deprivation (IMD),18126
smoking status and practice identifier (anonymised). The IMD is the official measure of127
relative deprivation for neighbourhoods in England. England can be divided into 32,844128
neighbourhoods each with around 1500 residents (650 households) and these are ranked129
from 1 (most deprived area) to 32,844 (least deprived) based on an aggregated measure130
of seven dimensions of deprivation.18 It is common practice to use the fifths of deprivation131
to give a summary of the deprivation where patients live, moving from the most deprived132
20% through to the most affluent 20%. Comorbidities were included where data are133
routinely collected and where an impact on antibiotic prescribing or outcome from antibiotic134
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prescribing might be anticipated. Clinical codes for these comorbidities were determined135
using the business rules defined in the NHS Quality Outcomes Framework (QOF).19 These136
included: cancer, coronary heart disease (CHD), chronic kidney disease (CKD), COPD,137
peripheral arterial disease (PAD), asthma, diabetes, stroke, and transient ischaemic attack138
(TIA). Any new record of the following pathogens during the year of study was extracted:139
C. difficile, VRE, and MRSA; no attempt was made to distinguish colonisation from140
infection. Codes used were READ Codes (Version 3) - CTV320 and those used for the141
data extract are shown in appendix 1; if any of these codes were present, the variable was142
considered to be present, otherwise they were considered to be not present.143
144
PenA records were defined using READ codes specified by the research team. Patients145
were considered to have PenA record if they had either a record of “sensitivity” or “allergy”146
to any penicillin class antibiotic agent (amoxicillin, ampicillin, penicillin V and G,147
flucloxacillin, piperacillin) recorded in their electronic health records on 1st April 2013. We148
combined allergy and sensitivity records because these terms are often used149
interchangeably.1150
151
Health Outcomes152
We ascertained if there was a record of a prescription of a subsequent antibiotic of a153
different class in the 28 days following the prescription of an index antibiotic agent; this154
has been used previously as a proxy marker of ‘lack of treatment response’.21 Mortality155
and healthcare associated infection (MRSA, Clostridioides difficile infection (CDI) and156
VRE) at any time during the one year study period were included as additional health157
outcomes.158
159
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Selection Bias160
Data for all patients available on ResearchOne who fulfilled the inclusion criteria were161
used for the analyses.162
163
Sample size164
The sample comprised data for all patients on ResearchOne who fulfilled inclusion criteria.165
We estimated a population of 2 million with a prevalence of 10% would yield an estimate of166
prevalence with a standard error of 0.02%.167
168
Statistical methods (including quantitative variables)169
Part 1: Cross sectional study170
Adjusted and unadjusted OR were calculated from cross tabulation of PenA records with171
potential factors affecting these records, and 95% CI reported. For convenience,172
continuous variables (age, GP practice list size and area deprivation (IMD) were173
categorised. This reduced the risk of inadvertent identification further during analysis,174
enabled handling of non-linear effects, and made interpretation of results easier. Adjusted175
OR were calculated from a logistic regression model which included a random intercept176
term to account for clustering of patients within general practice. The intra-class correlation177
coefficient is reported to enable the assessment of clustering.178
179
Part 2: Retrospective cohort study for associated health impacts180
Two patient cohorts were formed according to the PenA records at 1st April 2013 and181
patients in the cohort with a penicillin allergy record were then exact matched to patients in182
the cohort without a PenA record. Exact matching was undertaken according to the factors183
identified in Part 1: age, sex, ethnicity, IMD, comorbidities: asthma, cancer, CHD, CKD,184
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COPD, diabetes, PAD, smoking, stroke, TIA, and the proportion of patients with PenA185
record within the general practice. Any continuous variables were finely categorised to186
allow the exact matching process. All patients in the PenA cohort were then matched,187
according to all the factors above; multiple subclasses were formed which differed only in188
their PenA status. This meant that each PenA patient could be matched to multiple189
patients without a PenA record, who shared the same characteristics. Practices were also190
categorised according to the percentage of patients within them with a PenA record, and191
these categories were used in the exact matching as an additional factor. Following192
matching, each binary outcome, MRSA, C. difficile, 1-year mortality, was modelled within a193
binomial model using a log link and including all of the matching factors as covariates as194
well as PenA record. This is the currently recommended approach, which demands the195
controlling of factors even after matching.22 RR was reported from exponentiated196
coefficients along with 95% CI. The number of antibiotic prescriptions was modelled as a197
negative binomial regression with the same set of covariates. The incidence RR was198
calculated by exponentiating the coefficients. Patients were only counted once in this199
analysis. A propensity score matched model was used for a sensitivity analysis.200
201
Part 3: Retrospective cohort study for antibiotic prescribing202
A subset comprising all patients prescribed at least one antibiotic in the year 1/4/2013-203
31/3/2014 was used because only those having an infection requiring antibiotic treatment204
were considered with respect to type of antibiotic prescribed. Exact matching using the205
method of Part 2 was applied to the subset. Outcomes of interest were the prescription of206
specific antibiotic classes and were modelled by a binomial model with a log link function.207
Then exponentiated coefficients gave the RR of each antibiotic class. A value of the RR208
risk greater than 1.000 meant that, according to the fitted model, the antibiotic class was209
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more likely to be prescribed to those with a PenA record than those without, after210
controlling for age, sex, ethnicity, IMD, smoking status, comorbidities (asthma, cancer,211
CHD, CKD, COPD, diabetes, PAD, stroke, TIA), and the proportion of patients with PenA212
record within the general practice.213
214
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Results215
216
Participants217
2,350,803 adult patients met inclusion criteria and comprised the initial population for218
cross sectional analysis (Tables 1 and 2).219
220
Prevalence of penicillin allergy records.221
139,437 patients had a PenA record, giving a prevalence for the population of 5.9% (95%222
CI5.9-6.0%).223
224
Characteristics of patients with a penicillin allergy record.225
Women were more likely to have a recorded PenA, even after adjustment for possible226
confounders (Table 1). The prevalence increased significantly with increasing age (Table227
1). Rates of PenA varied considerably by general practice (IQR 3.8-8.2%); from the228
random intercept term, the calculated intra-class correlation (ICC) revealed that 7.2% of229
the variation in PenA records could be attributed to general practice. After adjustment, IMD230
status had a small but significant impact, and with more affluent patients more likely to231
have a record of allergy. The exception was patients with ‘unknown’ IMD status, which was232
associated with lower odds of a record of PenA; IMD status was not available for 11.1% of233
patients. The selected comorbidities were all associated with small but significantly234
increased odds of having a PenA record, with asthma having the highest (Table 2).235
236
Exact matching237
Part 2: 130,571 of 139,437 patients with a record of PenA were matched with 1,892,835 of238
2,211,366 patients. Exact matching results are shown in Table 3. Part 3: For those239
West 13
13
patients treated with an antibiotic, 45,831 with a record of PenA were matched with240
409,687 patients with no record.241
242
Penicillin allergy records and antibiotic prescribing243
In the exact matched analysis, patients with a PenA record received approximately 5%244
more antimicrobial prescriptions than those without a PenA record during the 12-months245
follow-up (Table 3). Macrolides, tetracyclines, cephalosporins, quinolones, clindamycin,246
nitrofurantoin and trimethoprim were all prescribed significantly more frequently in patients247
with a PenA record (Table 4). As expected, carbapenems and aztreonam were prescribed248
infrequently. Antibiotic prescribing patterns in the total population are shown in Tables S1249
and S2.250
251
Penicillin allergy record and health outcomes252
Compared to patients without a PenA record, those with a record had significantly253
increased risk of: death in the following year; re-prescription of a new antibiotic class within254
28 days and MRSA infection/colonisation (Tables 3, 5 and S3). A PenA record was255
associated with 6 in 1000 more deaths and 1 in 1000 more patients with MRSA. There256
was a non-statistically significant increase in risk of CDI. There were only two patients with257
VRE records and these were not analysed further. The propensity score matched258
sensitivity analysis found equivalent results (data not shown).259
260
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Discussion262
Key results263
A record of PenA affected 1 in 17 general practice patients, with considerable variation264
between practices. PenA records were associated with increasing age, being female, and265
co-morbidity. After matching for demographic factors and co-morbidities, a PenA record266
was associated with more antibiotic prescriptions, a different profile of antibiotic267
prescribing, a higher rate of re-prescription of a new antibiotic class within 28 days, greater268
MRSA burden and increased risk of death. There was little evidence of an impact on CDI,269
when confounding factors were taken into consideration.270
271
Strengths and weaknesses272
Use of routinely collected clinical data carries risk of bias, but exact matching was used to273
reduced this. Such studies are affected by data quality, so we purposefully chose274
conditions that are included in QOF because they are linked to health services payments275
and likely to be consistently and well recorded across general practices. There may be276
conditions that affect PenA recording that we have not included. The main concern with277
the use of exact matching is bias due to lack of matches; in this study the matching rate278
was very high (94%), minimising risk of bias due to lack of matches.279
280
Drug reactions can be recorded in different ways on SystmOne, and hence appear in281
ResearchOne, as either “sensitivities” or “allergies” so they were considered282
interchangeable in the analysis. This might be an over-simplification, but from GP283
stakeholder consultations and literature these terms seemed to be used interchangeably.23284
In addition, when patients move to a new GP there is a potential problem with the285
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correctness and completeness of the data migration process between GP systems with286
respect to recorded allergies and sensitivities. For example, migration might omit287
sensitivities, or might import at a coarser granularity. The more patient records move288
between practices, the more they are subject to any issues associated with these289
migration processes. IMD was not recorded in 11% of patients and this was associated290
with a lower rate of PenA records; we think that this may relate to patients whose291
postcodes were missing, invalid or newly assigned, or patients without a permanent292
residence but it is possible that it reflects generally poor record keeping. While this might293
result in an underestimate of the overall prevalence of PenA records it did not affect the294
exact matching analysis.295
296
We did not standardise the counting of antibiotic prescriptions to average daily quantities297
(ADQs) but we were primarily concerned with choice of agent in this analysis, rather than298
dose-related effects. Methods of testing for, diagnosing, and communicating MRSA and C.299
difficile infection vary between laboratories, but we could not see any reason why this300
would have a selective effect on either our patient groups. We know that there is301
inconsistency and a lack of consensus on what information is transferred from hospital302
records to general practice electronic health records. For this reason, we also collected all303
MRSA positive results and did not attempt to distinguish between MRSA colonisation and304
infection.305
306
ResearchOne data are likely to be representative of the general population because they307
came from a large number (400) of general practices in England. The similarity of our308
findings when compared with recent data from The Health Improvement Network (THIN)14309
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provides important validation of the use of these clinical databases in applied research, as310
these databases derive from different electronic health record systems.311
312
313
Prevalence of penicillin allergy records314
An allergy to penicillin has previously been reported in 4.5-15.6% of patients, depending315
on location and population, but none of these studies were a based on a general adult316
population.1,2,3,4,24,25 Our estimate of prevalence is lower than the National Institute of317
Health and Care Excellence (NICE) estimate of 10%1 probably because hospital patients318
are enriched for those with co-morbidites. The observed variation in recording of PenA319
between general practices, raises the possibility of under recording and therefore an320
underestimate of its prevalence. There are differences in the reported prevalence of PenA321
between the United States of America (US), which generally reports prevalence of over322
10%,2,3,24 and the UK and Europe where a lower prevalence has been reported,4,25 but323
these studies were generally small (single institution) or undertaken in select patient324
groups. The importance of this figure lies in the number of patients who are likely to have a325
true allergy to penicillin; probably fewer than 10% of those with an record of PenA.1 With a326
5.9% prevalence of PenA records, an estimated 3 million UK adults are affected.327
328
Patient characteristics associated with a penicillin allergy record329
Older women with co-morbidities were more likely to have a PenA record, while area330
deprivation (IMD) was associated with a reduced risk. General practice list size also had331
an effect, with increased records in medium size practices. Studies that explore the health332
impacts of penicillin records clearly need to account for these confounding factors. All the333
factors identified increase the possibility of being prescribed an antibiotic and, presumably,334
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the chance of having a reaction that is recorded as an allergy or sensitivity. All the selected335
comorbidities that we felt were likely to impact on infection risk were associated with a336
small but significant increased risk of a PenA record. Our assumption of increased337
infection risk was borne out by higher rates of all antibiotic prescriptions in patients with all338
the selected conditions (data not shown).339
340
Effects on antibiotic prescribing341
Even after matching for age, sex, IMD, smoking and comorbidities (asthma, cancer, CHD,342
CKD, COPD, diabetes, PAD, stroke, TIA) and prevalence of PenA records at the general343
practice, a PenA record was associated with altered and increased antibiotic prescribing.344
In keeping with previous mainly hospital-based studies, macrolides and tetracyclines were345
the most commonly prescribed antibiotics for patients with a PenA record,26 while the346
biggest impact (increase in relative risk) of the record was on clindamycin, tetracyclines347
and quinolones, similar to a recent primary care-based analysis from the Netherlands,348
which also found patients with a PenA record had a higher likelihood of receiving more349
than one antibiotic prescription (OR 2.56, 95% CI 2.05–3.20).7 This raises questions about350
the relative clinical effectiveness of non-penicillins and the possibility that patients with a351
PenA record receive less effective agents with more treatment failures. An alternative352
explanation is that patients with a PenA record are more prone to infection and also353
treatment failure. We attempted to account for this by controlling for comorbidities that are354
associated with an increased risk of infection but the increased rate of antibiotic355
prescribing remained. Trimethoprim and nitrofurantoin prescribing were included as a356
reference point because we initially thought these would not be affected by PenA status.357
The small but significant increase of trimethoprim RR might be accounted for by use in358
infections other than urinary tract infection (e.g. respiratory tract infections21) in patients359
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with a PenA record. Higher rates of nitrofurantoin prescribing in patients with a PenA360
record may indicate health seeking behaviour.361
362
Effects on health outcomes363
The observed increase in all-cause mortality in patients with a PenA record, even after364
matching for age, gender and comorbidity was surprising given the low mortality from365
infections managed in general practice. Increased mortality has been described previously366
in a US hospital-based study which found a 1.6-fold higher risk of dying during367
hospitalisation associated with a PenA record (crude OR 1.56, 95% CI 1.20-2.04),27 and it368
has been suggested that a PenA record might result in suboptimal therapy, particularly for369
hospitalised patients, where for example, penicillins are considered treatment of choice for370
Staphylococcus aureus bloodstream infection.371
372
Healthcare associated infection pathogens.373
MRSA and CDI rates were low as would be expected in a general practice population but374
the risk of MRSA colonisation/infection was higher among those with a PenA record. There375
were no records of VRE, confirming this as a pathogen whose relevance is currently376
restricted to secondary care. A recent study using THIN, a UK electronic health record377
database of general practice patients, also found an increased risk of MRSA in patients378
with a PenA of similar magnitude (multivariable adjusted hazard ratio 1.69).14 In the US,379
penicillin allergic hospital patients were found to have 23.4% (95% CI, 15.6% to 31.7%)380
more C. difficile, 14.1% (95% CI, 7.1% to 21.6%) more MRSA, and 30.1% (95% CI, 12.5%381
to 50.4%) more VRE infections than expected compared with control subjects.3 Many382
factors affect the risk of MRSA infection, including antibiotic prescribing practices.28383
Observational studies show an association between MRSA colonisation/infection and384
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various classes of antibiotics:-cephalosporins,11,12 carbapenems,13 clindamycin13 and385
fluoroquinolones,12 so there is a plausible, potential mechanism for the increased risk. The386
THIN analysis found that half the increased risk of MRSA was mediated through387
fluoroquinolone, clindamycin and macrolide prescribing. While we saw a non-statistically388
significant increased risk of CDI in patients with a PenA (RR 1.22), the THIN analysis389
found a significantly increased risk of CDI (adjusted hazzard ratio 1.26), perhaps because390
of the longitudinal nature of that study allowing longer follow-up for each patient.14391
392
Penicillin prescribing393
Patients who report a PenA are not usually prescribed penicillins5 so finding that nearly 1394
in 25 patients with a PenA record had been prescribed a penicillin, subsequent to the date395
of their allergy record, was unexpected. Possible explanations include: Data entry errors or396
GPs consciously “over-ruling” PenA alerts, perhaps because a patient may have an allergy397
to a specific agent but can tolerate other penicillins. Re-prescription of a new antibiotic398
class within 28 days was associated with a PenA record, this has been used a marker of399
treatment response failure in some studies but there are other explanations why this may400
have occurred, for example, it is possible that patients returned when they noticed a401
penicillin had been prescribed, or experienced an adverse reaction, or were non-402
compliant.403
404
Conclusions405
The prevalence of PenA records in adults in general practice suggests there are three406
million affected patients in the UK. Identifying patients without a current PenA (e.g. by a407
pre-emptive penicillin allergy testing strategy) has the potential to improve antibiotic408
prescribing, enabling more patients to receive first line therapy for infections. This409
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antimicrobial stewardship strategy has potential to improve clinical outcomes and help410
contain antibiotic resistance. Current services are unlikely to cope with the increased411
demand that additional testing would require so service provision needs to be reviewed; a412
safe streamlined testing pathway is under evaluation* to avoid over-burdening the existing413
allergy service.414
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525
Characteristic Penicillin
allergy record
No penicillin
allergy record
Unadjusted OR
(95% CI)
Adjusted OR*
(95% CI)
Overall count 139,437 (5.9%) 2,211,366
Gender
Male 51,754 (4.4%) 1,115,192 1.00 (Ref.) 1.00
Female 87,683 (7.4%) 1,096,157 1.72 (1.70-1.74) 1.72 (1.70-1.74)
Age
18–24 10,160 (4.0%) 245,248 1.00 1.00
25–34 17,611 (4.3%) 390,920 1.09 (1.06-1.11) 1.10 (1.07-1.13)
35–44 22,321 (5.7%) 373,061 1.44 (1.41-1.48) 1.42 (1.38-1.45)
45–54 25,760 (6.2%) 392,976 1.58 (1.55-1.62) 1.49 (1.45-1.54)
55–64 22,205 (6.5%) 318,181 1.68 (1.64-1.73) 1.50 (1.46-1.53)
65–74 20,338 (7.2%) 263,051 1.87 (1.82-1.91) 1.50 (1.46-1.54)
75–100 21,042 (8.5%) 227,929 2.23 (2.17-2.28) 1.59 (1.55-1.64)
IMD (fifths)
Most deprived 22,075 (5.3%) 396,076 1.00 1.00
Deprived 24,618 (5.9%) 393,822 1.12 (1.10-1.14) 1.04 (1.02-1.06)
Average 27,993 (6.7%) 389,731 1.29 (1.27-1.31) 1.07 (1.05-1.09)
Affluent 27,380 (6.6%) 390,678 1.26 (1.23-1.28) 1.07 (1.04-1.09)
Most affluent 27,178 (6.5%) 390,902 1.25 (1.22-1.27) 1.07 (1.04-1.10)
Unknown 10,193 (3.9%) 250,157 0.73 (0.71-0.75) Dropped
Practice list size
West 25
25
0–5,000 15,656 (5.4%) 275,288 1.00 1.00
5,000–9,999 52,556 (5.9%) 834,541 1.11 (1.09-1.13) 1.05 (0.98-1.12)
10,000–14,999 49,688 (6.3%) 739,903 1.18 (1.16-1.20) 1.17 (1.08-1.26)
15,000–19,999 15,037 (6.2%) 229,617 1.15 (1.13-1.18) 1.19 (1.05-1.34)
20,000–75,000 6,285 (4.6%) 129,614 0.85 (0.83-0.88) 0.99 (0.84-1.17)
Unknown 215 (8.2%) 2,403 1.57 (1.37-1.81) Dropped
526
Table 1. Characteristics of patients with and without a penicillin allergy record in a sample527
of antibiotic treated general practice patients in England. *The adjusted analysis was528
undertaken with complete cases only, that is those with complete data for all covariates;529
IMD, index of multiple deprivation.530
531
532
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Condition
Penicillin
allergy record
No penicillin
allergy record
Unadjusted OR
(95% CI)
Adjusted OR
(95% CI)
No
conditions
43,199 (4.6%) 886,940 1.00 1.00
1 condition 58,041 (5.9%) 929,994 1.28 (1.27-1.30) -
2 conditions 24,226 (8.1%) 275,509 1.81 (1.78-1.84) -
3 or more 13,971 (10.5%) 118,923 2.41 (2.36-2.46) -
Asthma 25,052 (8.9%) 255,637 1.68 (1.65-1.70) 1.58 (1.56-1.61)
Cancer 9,827 (8.9%) 100,723 1.59 (1.56-1.62) 1.18 (1.15-1.21)
CHD 8,845 (9.1%) 88,748 1.62 (1.58-1.66) 1.23 (1.20-1.26)
CKD 11,228 (9.5%) 106,585 1.73 (1.69-1.76) 1.18 (1.15-1.21)
COPD 8,130 (10.7%) 67,587 1.96 (1.92-2.01) 1.41 (1.37-1.45)
DM 11,280 (8.1%) 127,784 1.44 (1.41-1.46) 1.18 (1.16-1.21)
PAD 1,647 (9.5%) 15,712 1.67 (1.59-1.76) 1.16 (1.10-1.22)
Smoker 74,720 (6.5%) 1,078,500 1.21 (1.20-1.23) 1.11 (1.10-1.13)
Stroke 2,782 (9.2%) 27,591 1.61 (1.55-1.68) 1.15 (1.11-1.20)
TIA 2,437 (9.8%) 22,328 1.74 (1.67-1.82) 1.19 (1.13-1.24)
536
Table 2: Counts, percentages and odds ratios of penicillin allergy record compared to537
patient disease registration. *The adjusted analysis was undertaken with complete cases538
only, that is those with complete data for all covariates. The analysis adjusted for all539
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27
variables listed in tables 1 and 2. CHD, coronary heart disease; CKD, chronic kidney540
disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; TIA,541
transient ischaemic attack; PAD, peripheral arterial disease.542
543
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544
Relative risk 95% CI p
Antibiotic prescribing
Any antibiotic 1.05 1.04-1.06 <0.001
Health outcomes,
absolute number (%)
Mortality 1.08 1.03-1.14 0.002
CDI 1.22 0.80-1.87 0.359
MRSA 1.90 1.50-2.41 <0.001
545
Table 3: Health outcomes in the exact-matched cohort of general practice patients, with546
(n= 130571) and without (n= 1,892,835) a record of penicillin allergy. CDI, Clostridioides547
difficile infection. MRSA, Methicillin resistant Staphylococcus aureus; aHR, adjusted548
hazard ratio.549
550
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Relative
risk
95%
Confidence
interval
p
Antibiotic
Clindamycin 5.47 4.83-6.20 <0.001
Macrolide 4.03 3.99-4.08 <0.001
Quinolone 2.10 2.02-2.19 <0.001
Cephalosporin 2.05 1.99-2.12 <0.001
Tetracycline 1.91 1.88-1.94 <0.001
Nitrofurantoin 1.09 1.07-1.11 <0.001
Trimethoprim 1.04 1.03-1.06 <0.001
Penicillin 0.15 0.14-0.15 <0.001
Carbapenem - - -
Monobactam - - -
Health outcomes
Re-prescription of a new
antibiotic class within 28
days
1.33 1.31-1.35 <0.001
Table 4: Antibiotic prescribing patterns in an exact-matched cohort of general practice552
patients, prescribed antibiotics, with and without a record of penicillin allergy.553
554
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Health outcome Penicillin
allergy
No penicillin
allergy
P value
139,437 2,211,366
Re-prescription of a new
antibiotic class within 28 days
10,111 (7.3%) 89,191 (4.0%) <0.001
Mortality, absolute number
(%)
2056 (1.5%) 2,0521 (0.9%) <0.001
CDI, absolute number (%) 26 (0.0%) 256 (0.0%) 0.027
MRSA, absolute number (%) 95 (0.1%) 674 (0.0%) <0.001
557
Table 5. Health outcomes in the total cohort of general practice patients, with and without558
a record of penicillin allergy. CDI, Clostridioides difficile infection. MRSA, Methicillin559
resistant Staphylococcus aureus.560
561
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